Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 70,542	$ 61,761
Marketable securities	16,784	0
Trade receivables, net	9,811	0
Partnership receivables	1,790	1,197
Inventory	1,656	0
Clinical trial retainers	1,181	355
Other prepaid expenses and other current assets	2,972	2,195
Total current assets	104,736	65,508
Property and equipment, net	276	343
Operating lease right-of-use asset	178	903
Other assets	151	158
Total assets	105,341	66,912
Current liabilities:
Accounts payable	2,712	3,380
Accrued clinical trial costs and contract research	5,046	4,550
Employee-related Liabilities, Current	4,963	3,082
Other accrued liabilities	5,421	1,381
Operating lease liability	11	369
Loans payable, net of discount	0	1,056
Deferred revenue	578	1,974
Deferred research and development reimbursements	0	164
PIPE Warrant liability	0	199
Other liabilities (Note 6)	0	790
Total current liabilities	18,731	16,945
Loans payable, net of current portion and discount	37,960	12,716
Deferred revenue, non-current	0	578
Operating lease liability, non-current	0	336
Other liabilities, non-current (Note 6)	2,780	1,043
Total liabilities	59,471	31,618
Stockholders’ equity:
Preferred stock, $.001 par value: 5,000 shares authorized at December 31, 2021 and December 31, 2020; no shares issued and outstanding at each of December 31, 2021 and December 31, 2020	0	0
Common stock, $.001 par value: 50,000 shares authorized at December 31, 2021 and December 31, 2020; 34,475 shares issued and outstanding at December 31, 2021 and 26,883 issued and outstanding at December 31, 2020	34	27
Additional paid-in capital	720,386	656,472
Accumulated other comprehensive loss	(3)	0
Accumulated deficit	(674,547)	(621,205)
Total stockholders’ equity	45,870	35,294
Total liabilities and stockholders’ equity	$ 105,341	$ 66,912